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Myostatin inhibition prevents 
skeletal muscle pathophysiology in 
Huntington’s disease mice
Marie K. Bondulich1,2,3, Nelly Jolinon2, Georgina F. Osborne1,2,3, Edward J. Smith1,2,3, Ivan 
Rattray2, Andreas Neueder1,2,3, Kirupa Sathasivam1,2,3, Mhoriam Ahmed1,4, Nadira Ali1,2,3, 
Agnesska C. Benjamin1,2,3, Xiaoli Chang5, James R. T. Dick1,4, Matthew Ellis6,7, Sophie A. 
Franklin1,2,3, Daniel Goodwin1,2,3, Linda Inuabasi2, Hayley Lazell1,2,3, Adam Lehar5, Angela 
Richard-Londt6,7, Jim Rosinski8, Donna L. Smith2, Tobias Wood9, Sarah J. Tabrizi3,7, Sebastian 
Brandner  6,7, Linda Greensmith1,4, David Howland8, Ignacio Munoz-Sanjuan8, Se-Jin Lee5 & 
Gillian P. Bates  1,2,3
Huntington’s disease (HD) is an inherited neurodegenerative disorder of which skeletal muscle atrophy 
is a common feature, and multiple lines of evidence support a muscle-based pathophysiology in HD 
mouse models. Inhibition of myostatin signaling increases muscle mass, and therapeutic approaches 
based on this are in clinical development. We have used a soluble ActRIIB decoy receptor (ACVR2B/
Fc) to test the effects of myostatin/activin A inhibition in the R6/2 mouse model of HD. Weekly 
administration from 5 to 11 weeks of age prevented body weight loss, skeletal muscle atrophy, muscle 
weakness, contractile abnormalities, the loss of functional motor units in EDL muscles and delayed 
end-stage disease. Inhibition of myostatin/activin A signaling activated transcriptional profiles to 
increase muscle mass in wild type and R6/2 mice but did little to modulate the extensive Huntington’s 
disease-associated transcriptional dysregulation, consistent with treatment having little impact on HTT 
aggregation levels. Modalities that inhibit myostatin signaling are currently in clinical trials for a variety 
of indications, the outcomes of which will present the opportunity to assess the potential benefits of 
targeting this pathway in HD patients.
Huntington’s disease (HD) is an inherited progressive neurodegenerative disorder for which the age of onset is 
generally in midlife. It is caused by a CAG repeat expansion in the first exon of the huntingtin (HTT) gene that 
results in an abnormally long polyglutamine tract in the huntingtin protein (HTT)1. Symptoms include problems 
with motor coordination, neuropsychiatric symptoms and cognitive decline; and there are no disease-modifying 
treatments2. The mutant form of the HTT protein aggregates into oligomeric and fibrillary structures which are 
deposited in the brains of HD patients3,4 and neurodegeneration occurs in the striatum, cortex, hypothalamus 
and other brain regions5. There is increasing evidence to indicate that Huntington’s disease is also associated with 
pathological processes that occur in peripheral tissues, including skeletal muscle6. Treatments targeted to tissues 
and organs outside the CNS have the potential to substantially improve the quality of life of HD patients, either in 
the absence of disease modifying treatments or combined with CNS-targeted therapies7.
Mouse models of HD include mice that are transgenic for the 5′ region of the human HTT gene (e.g. R6/2), 
those transgenic for the entire human HTT gene (e.g. BACHD and YAC128) and a range of knock-in models 
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(e.g. HdhQ150 and zQ175)8. In recent years, we have performed detailed comparative analyses of the R6/2 mouse 
model9 and HdhQ150 knock-in mice10 and found that at late stage disease (14 weeks for R6/2 and 22 months 
for homozygous HdhQ150) the phenotypes of these two models are extremely similar11–16, the main difference 
between the lines being the age at phenotype onset and the rate of disease progression. The R6/2 mouse is trans-
genic for a genomic DNA fragment encoding exon 1 of human HTT and is a model of the incomplete splicing 
event that occurs in all HD knock-in mouse models, YAC128 and BACHD mice17, and in HD patient tissues18, 
resulting in an exon 1 – intron 1 mRNA that in all cases produces the highly pathogenic exon 1 HTT protein. 
Both the R6/2 and HdhQ150 models develop a progressive failure to gain body weight, followed by weight loss11 
and a highly comparable skeletal muscle atrophy and underlying muscle pathophysiology19. The skeletal muscle 
phenotype manifests as a uniform muscle fibre atrophy19–21 and functional deficits19,22, associated with the forma-
tion of nuclear inclusions13,20, transcriptional dysregulation19,23–25, energetic disturbances19,25, ion channel per-
turbations26, alterations in protein synthesis and degradation pathways27 and an apparent dissociation of trophic 
signaling between motor neurons and skeletal muscle21. The investigation of the mechanisms underlying muscle 
pathology in HD mouse models is likely to lead to insights into the muscle atrophy and loss of muscle strength 
that has been reported in HD patients (for review, see28).
Myostatin is a member of the transforming growth factor β super family of secreted growth factors that is 
synthesized as a full length precursor and becomes cleaved into an amino-terminal propeptide and carboxy ter-
minal mature region29. It has been shown to be a muscle specific regulator of muscle size, and the knock-out of 
myostatin results in muscle hypertrophy and a reduction in adipose tissue mass30,31. Binding of myostatin and 
activin A to the activin A receptor type IIB (ActRIIB) on muscle cell membranes, activates SMAD 2/3-mediated 
transcription, which stimulates FOXO-dependent transcription increasing muscle protein degradation. SMAD 
activation also inhibits muscle protein synthesis by suppressing AKT signaling (for review see32). A soluble form 
of the activin type IIB receptor (ACVR2B/Fc) has been developed to compete with the natural receptor for cir-
culating agonists and this caused a dramatic increase in muscle mass when injected into wild type (WT) mice33. 
Therefore, agents that block the myostatin signaling pathway have the potential to treat human disease associated 
with cachexia e.g. cancer, chronic kidney disease and chronic heart failure, as well as neuromuscular diseases32.
We have used the ACVR2B/Fc soluble receptor to test whether the inhibition of myostatin/activin A sign-
aling might prevent or decrease skeletal muscle atrophy and restore muscle function in mouse models of HD. 
Administration of ACVR2B/Fc to R6/2 mice from 5 weeks of age, completely prevented deficits in body weight 
gain, muscle atrophy, grip strength, muscle function and motor unit loss and also delayed end-stage disease. A 
range of therapeutic agents that inhibit myostatin signaling are currently being tested in clinical trials for a num-
ber of indications34, the outcomes of which will provide the opportunity to design clinical trials to treat muscle 
atrophy in people affected with HD.
Results
Treatment with ACVR2B/Fc prevents body weight loss, grip strength deficits and muscle atro-
phy in R6/2 mice. We first set out to determine whether the inhibition of myostatin/activin A signaling 
might reduce the extent of muscle atrophy that occurs in the R6/2 mouse model of HD. The soluble ActRIIB 
receptor (ACVR2B/Fc) was administered by a subcutaneous weekly 10 mg/kg injection to both WT and R6/2 
male and female mice (n = 5 per gender per genotype) from 5 to 11 weeks of age, and mice were sacrificed one 
week later at 12 weeks. Both male and female R6/2 mice developed a progressive failure to gain weight (Fig. 1A). 
Treatment with ACVR2B/Fc increased the body mass of both wild type (WT) and R6/2 mice as compared to their 
vehicle treated littermates and in the case of R6/2 mice, this completely prevented the decreased body weight phe-
notype (Fig. 1A). Similarly, fore limb grip strength was progressively impaired in both male and female R6/2 mice 
(Fig. 1B). Treatment with the receptor decoy resulted in an increase in fore limb grip strength in both WT and 
R6/2 mice as compared to vehicle treated littermates, and again completely prevented the R6/2 deficits (Fig. 1B). 
At sacrifice, the tibialis anterior (TA), quadriceps and gastrocnemius skeletal hind limb muscles were weighed. All 
three muscles showed a marked degree of atrophy in R6/2 mice (Fig. 1C). Treatment with ACVR2B/Fc increased 
muscle mass in both WT and R6/2 mice and, once more, in the case of R6/2, the weight of all three muscles had 
been restored to WT levels (Fig. 1C). In contrast, there was no effect on brain atrophy (Fig. S1A) or disease-as-
sociated changes in heart weight (Fig. S1A). Treatment with ACVR2B/Fc had been equally effective in male and 
female mice and, therefore, all further experiments were performed on female mice only.
To determine whether ACVR2B/Fc treatment had had an impact on body fat levels, we acquired magnetic 
resonance imaging (MRI) data using a 3-point Dixon technique to separate fat and water images. However, this 
approach did not detect a statistically significant difference between the treatment groups (Table S1).
Treatment with ACVR2B/Fc prevents muscle fibre atrophy. The skeletal muscle atrophy that occurs 
in R6/2 mice has previously been studied in detail and no evidence was found of changes typically associated with 
muscle pathology other than a diffuse atrophy20,21. The adult neuromuscular innervation pattern develops nor-
mally and the incidence of abnormalities at the neuromuscular junction was very low and only occurred in ani-
mals close to end stage disease21. The only prominent morphological change was a severe generalized atrophy of 
all muscle fibres that occurred in both fibre types20,21. Therefore, to investigate the effect of ACVR2B/Fc treatment 
on muscle pathology, we measured the lesser diameters of fibres in the TA and quadriceps muscles of WT and 
R6/2 mice that had been treated with ACVR2B/Fc or vehicle. We found that there was a statistically significant 
difference in the fibre diameters between WT and R6/2 quadriceps and TA muscles (Fig. 2) and that ACVR2B/
Fc treatment resulted in a statistically significant increase in the fibre diameter in both cases. Representative plots 
for the range of fibre diameters for the WT and R6/2 quadriceps and TA muscle treated with either vehicle or 
ACVR2B/Fc are illustrated in Fig. 2. ACVR2B/Fc treatment increased fibre diameter in the quadriceps (p < 0.001) 
and the TA (p = 0.061) of R6/2 mice.
www.nature.com/scientificreports/
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Treatment with ACVR2B/Fc improved muscle function in R6/2 mice. Neuromuscular function was 
assessed for the extensor digitorum longus (EDL) and TA muscles after treatment of female mice with either 
vehicle or ACVR2B/Fc at 12 weeks of age as compared to their littermate controls. We began by measuring the 
isometric muscle tension of these two muscles to assess the effect of ACVR2B/Fc on the contractile abnormali-
ties that we have previously described in R6/2 mice19,22. EDL is normally a fast twitch muscle that contracts and 
relaxes rapidly. In R6/2 mice, EDL took longer than WT EDL to exert a maximum twitch and then longer to relax 
(Fig. 3A and C). Upon treatment, the time to reach maximum twitch force was restored (Fig. 3A). In R6/2 mice 
TA muscles take the equivalent time as WT TA muscles to reach the peak force but take longer to relax (Fig. 3B 
and D). ActRIIB treatment completely restored the contractile dysfunction in the R6/2 TA (Fig. 3D).
Next, we measured the maximum tetanic force exhibited by the EDL and TA muscles in ACVR2B/Fc and 
vehicle treated WT and R6/2 mice. The EDL and TA muscle of R6/2 mice were weaker as compared to those from 
WT littermates (Fig. 3E and F); ACVR2B/Fc treatment increased R6/2 EDL strength to WT levels and there was 
a slight increase in the strength of the R6/2 TA muscles (87.2 ± 8.2 g as compared to 68.7 ± 4.5 g, p < 0.1) (Fig. 3E 
and F).
Figure 1. Treatment with ACVR2B/Fc restores deficits in body weight, grip strength and muscle mass in R6/2 
mice. (A) ACVR2B/Fc treatment resulted in a progressive weight gain in both WT and R6/2 mice and prevented 
body weight loss in R6/2 mice. (B) ACVR2B/Fc treatment resulted in a progressive increase in fore-limb grip 
strength in both WT and R6/2 mice and prevented grip strength deficits in R6/2 mice. (C) Treatment with 
ACVR2B/Fc increased muscle mass in both WT and R6/2 mice with the consequence that the R6/2 muscle mass 
at 12 weeks of age (genders combined) is equivalent to that of wild type mice for quadriceps, gastrocnemius and 
tibialis anterior hind limb skeletal muscles. Statistical analysis was two-way ANOVA with post-hoc Bonferroni 
correction (see Table S8 for main effects and Table S9 for multiple comparisons). The statistical significance 
between values for ACVR2B/Fc treated and vehicle treated R6/2 mice is depicted: *p < 0.05; **p < 0.01; 
***p < 0.001. n = 5 mice per gender per genotype. All data presented as means ± SEM.
www.nature.com/scientificreports/
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EDL muscles in WT mice are innervated by approximately 30 functional motor units35 and we have previously 
shown that this is reduced to approximately 20 motor units in the R6/2 EDL at 12 weeks of age and then further 
decreased to approximately 10 units by 14 weeks19. The number of functionally active motor neurons that inner-
vate the EDL was assessed in vehicle and ACVR2B/Fc treated 12 week old WT and R6/2 mice. Representative 
examples of motor unit recordings and the mean motor unit number are illustrated in Fig. 3G. ACVR2B/Fc 
treatment completely prevented the loss of functional motor units in R6/2 mice and had no effect on motor unit 
number in WT mice.
Treatment with ACVR2B/Fc delays end-stage disease but does not improve motor impair-
ments. The progressive impairment of motor function is a cardinal feature of HD mouse models, to which 
both central nervous system (CNS)-driven and skeletal muscle-driven pathogenic mechanisms might contribute. 
Given that ACVR2B/Fc treatment completely rescued muscle atrophy and weakness, this provided an opportu-
nity to dissect the extent to which a muscle-based pathology might contribute to motor related tasks. To address 
this, we dosed female R6/2 mice with either vehicle or ACVR2B/Fc from five weeks of age. A vehicle treated WT 
group was included to allow an estimation of effect size and to provide a control for any adverse effects (Fig. 4). 
Body weight and fore limb and hind limb grip strength were measured until 15 weeks of age. Mice were assessed 
for performance on an accelerating rotarod until 12 weeks of age and activity measures until 15 weeks. As before, 
ACVR2B/Fc treatment rescued deficits in body weight (Fig. 4A), and this rescue was maintained until 15 weeks 
of age. End-stage disease, as defined by the criteria in Table S2, was statistically significantly delayed in treated 
mice (Fig. 4B). Due to the development of an anal prolapse, two ACVR2B/Fc treated R6/2 mice were culled (on 
days 106 and 122) and these were not included in the final analysis. Although the deficits in grip strength were 
completely restored (Fig. 4C), there was no improvement in the decline in rotarod performance or the ensuing 
hypoactivity in the open field (Fig. 4D). Therefore, the restoration in muscle mass and strength did not improve 
the motor-related tasks measured here, suggesting that the pathogenic basis of these impairments is driven by 
CNS-related mechanisms.
ACVR2B/Fc treatment and huntingtin aggregation. HTT aggregation in the form of nuclear 
inclusions has been detected in the skeletal muscle of both R6/2 and the Hdh150 knock-in HD models13,20,21. 
Quantification of the aggregate load using the Seprion ELISA has demonstrated that statistically significant levels 
of aggregated HTT can be detected in R6/2 quadriceps by 8 weeks of age36 and that the aggregate load is higher in 
the TA than in the quadriceps or gastrocnemius/plantaris19.
We began by applying the Seprion ELISA to investigate the effect of ACVR2B/Fc treatment on HTT aggre-
gation in R6/2 quadriceps and TA muscles from 12 week old mice that had been treated with ACVR2B/Fc or 
vehicle. This suggested that treatment had led to a reduction in the aggregate load in both TA (p < 0.01) and 
quadriceps (p = 0.05) (Fig. 5A). HTT aggregation is the earliest phenotype to have been detected in skeletal mus-
cle, and therefore, this result suggested that ACVR2B/Fc treatment might have had disease modifying properties. 
However, alternatively, the ACVR2B/Fc induced hypertrophy might have diluted the level of HTT aggregation 
in a given tissue mass, in which case, the degree of HTT aggregation could have remained unchanged, and our 
Seprion ELISA results might have been misleading. To investigate this further, TA sections were immunostained 
with antibodies to HTT (S830), and laminin, counterstained with DAPI (Fig. S2A and C), and immunofluo-
rescence signals were quantified as illustrated in the work flow in Fig. S2B. The number of DAPI-stained nuclei 
in the regions of interest (ROI) was increased in R6/2 TA as compared with WT, which is consistent with the 
myofibre atrophy that had occurred in this R6/2 muscle (Figs 5B and S3A). Conversely, the number of nuclei 
Figure 2. ACVR2B/Fc treatment prevents muscle fibre atrophy. (A) the lesser fibre diameter of myofibres in 
the TA and quadriceps of WT and R6/2 mice treated with ACVR2B/Fc or vehicle. Fibre counts were obtained 
from between 3 and 8 sections per mouse, n = 3 or 4 mice/treatment group. The WT muscle fibre diameters 
were greater than those for R6/2: quadriceps (F(13,10) = 28.82, p ≤ 0.001), TA (F(15,12) = 10.29, p = 0.008). 
ACVR2B/Fc treatment increased the fibre diameter in both cases: quadriceps (F(13,10) = 92.8, p ≤ 0.001) and TA 
(F(15,12) = 12.73, p = 0.004). ACVR2B/Fc treatment increased fibre diameter in the quadriceps (p < 0.001) and 
the TA (p = 0.061) of R6/2 mice. Representative traces from individual mice are depicted. Statistical analysis was 
two-way ANOVA with post-hoc Bonferroni correction.
www.nature.com/scientificreports/
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had decreased in both WT and R6/2 TA in response to ACVR2B/Fc treatment, consistent with the hypertrophic 
response (Figs 5B and S3A). The average size of the nuclei, as determined by DAPI pixels, was unchanged between 
WT and R6/2 TA and did not change upon treatment in either case (Figs 5B and S3A).
To investigate the pattern and level of aggregation we quantified the level of S830 immunofluorescence. There 
were an equivalent number of S830 reactive inclusions in the ROI in R6/2 TA muscle that had been treated with 
either vehicle or with ACVR2B/Fc (Fig. 5C) although the average size of the inclusions (as measured in red pix-
els) was greater in the ACVR2B treated muscle (Fig. 5C). Previous studies have documented the formation of 
nuclear inclusions in the skeletal muscle of HD mouse models13,20, however, our immunostaining clearly demon-
strated that cytoplasmic inclusions were also present (Fig. S2C). To compare the level of aggregated HTT between 
the nucleus and cytoplasm, we performed an unbiased examination of the subcellular localization of the aggre-
gates in the vehicle and ACVR2B/Fc treated R6/2 TA muscle. Approximately 70% of the S830 immunoreactivity 
co-localized with DAPI staining (Figs 5D and S3B) for both treatment groups, corresponding to approximately 
55% of inclusions occurring in the nucleus (Fig. 5D). This is consistent with our observation that the nuclear 
inclusions tended to be larger than those in the cytoplasm.
Figure 3. Treatment with ACVR2B/Fc improves muscle function in R6/2 mice. (A–D) Contractile dysfunction 
of the R6/2 EDL muscles was assessed by measuring twitch tension: the time to peak and half relaxation 
time and this was corrected by ACVR2B/Fc treatment in both EDL (A,C) and TA (B,D) muscles. (E,F) The 
maximum tetanic force in mice treated with ACVR2B/Fc and vehicle. The maximum EDL (E) and TA (F) forces 
were decreased in R6/2 mice and completely rescued in mice treated with ACVR2B/Fc. (G) Examples of motor 
unit traces and the quantification of functional motor units. The number of functional motor units was reduced 
in R6/2 EDL muscles and this was restored in treated mice. Statistical analysis was two-way ANOVA with post-
hoc Bonferroni correction (see Table S8 for main effects and Table S9 for multiple comparisons). Statistically 
significant differences between vehicle treated WT and vehicle treated R6/2: #p < 0.05, ###p < 0.001; statistically 
significant differences between ACVR2B/Fc treated R6/2 and vehicle treated R6/2: *p < 0.05; **p < 0.01; 
***p < 0.001. n = 11 WT vehicle (EDL), n = 12 WT vehicle (TA), n = 8 WT ACVR2B/Fc (EDL and TA), n = 14 
R6/2 vehicle (EDL and TA), n = 12 R6/2 ACVR2B/Fc (EDL and TA). All data presented as means ± SEM. The 
baseline WT and R6/2 vehicle treated phenotype data were previously published10.
www.nature.com/scientificreports/
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We next examined the frequency and size of nuclear inclusions between R6/2 TA muscle that had been treated 
with ACVR2B/Fc and vehicle. Given that the average size of all inclusions per ROI was larger in ACVR2B/Fc 
treated muscle (Fig. 5C), that the total level of S830 signal in the nucleus was equivalent between treatment 
groups (Figs 5D and S3C) and that there were fewer nuclei in ACVR2B/Fc treated muscle (Fig. 5B), we asked 
whether the nuclear inclusions were larger in the ACVR2B/Fc treated TA. We found that the number of inclu-
sions that co-localised with the DAPI staining was equivalent between the two treatment groups (Fig. 5E); that 
there was a trend toward an increase in the percentage of nuclei containing inclusions in the ACVR2B/Fc treated 
TA (p = 0.097) (Fig. 5E) and that the size of the nuclear inclusions was greater in the ACVR2B/Fc treated TA 
(Fig. 5E). These data are consistent with the ACVR2B/Fc treated TA having fewer nuclei per ROI (Fig. 5B), of 
which a higher percentage have larger inclusions than in the vehicle treated TA.
Skeletal muscle regenerates in response to injury and Pax7 expressing satellite cells are the major or only 
mediators of myofibre regeneration in the adult mouse37. After multiple rounds of injury, the satellite pool is 
maintained through a process of self-renewal37. We found an increased level of Pax7 expression in R6/2 TA as 
Figure 4. Treatment with ACVR2B/Fc delays end-stage disease, but has no effect on rotarod performance or 
activity measures. (A) ACVR2B/Fc treatment completely prevented the progressive loss in body weight loss 
that occurs in R6/2 mice. The effect was such that R6/2 mice were significantly heavier than WT mice at some 
ages (Table S9). (B) Kaplan-Meier curve showing that ACVR2B/Fc treatment delays end-stage disease in R6/2 
mice (Chi = 8.764, p < 0.01 Mantel-Cox log-rank test). (C) ACVR2B/Fc treatment completely prevented the 
progressive loss in fore-limb as well as the combined fore- and hind-limb grip strength that occurs in R6/2 
mice. The effect was such that R6/2 mice were significantly stronger than WT mice at some ages (Table S9) (D) 
ACVR2B/Fc had no effect on the impairment in R6/2 rotarod performance or hypoactivity. Statistical analysis 
was two-way ANOVA with post-hoc Bonferroni correction (see Table S8 for main effects and Table S9 for 
multiple comparisons). The statistical significance between values for ACVR2B/Fc treated and vehicle treated 
R6/2 mice is depicted: *p < 0.05; **p < 0.01; ***p < 0.001. WT vehicle, n = 13; R6/2 vehicle, n = 17; R6/2 
ACVR2B/Fc, n = 14. All data presented as means ± SEM.
www.nature.com/scientificreports/
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compared to WT at 12 weeks of age suggesting that the satellite cell pool comprises a greater percentage of total 
nuclei in R6/2 than in WT mice. Treatment with ACVR2B/Fc brought the level of Pax7 expression back toward 
WT levels, indicating that the percentage of nuclei expressing Pax7 is lower in ACVR2B/Fc treated than in vehicle 
treated R6/2 mice (Fig. 5F).
ACVR2B/Fc activates a transcriptional program to increase muscle mass, with little impact 
on HD-related transcriptional dysregulation. Transcriptional dysregulation is a well-established 
Figure 5. ACVR2B/Fc treatment and HTT aggregation. (A) ACVR2B/Fc treatment results in a decrease in the 
aggregate load in R6/2 TA and quadriceps muscles as assessed by the Seprion ELISA. WT vehicle, n = 5; WT 
ACVR2B/Fc, n = 10; R6/2 vehicle n = 10; R6/2 ACVR2B/Fc, n = 9. WT background signal derives from the 
substrate. (B) Number of DAPI stained nuclei per ROI and average nucleus size in DAPI pixels. (C) Number 
of S830 inclusions per ROI and average inclusion size in pixels. (D) Percentage of S830 signal co-localized with 
DAPI and percentage of inclusions localized to the nucleus. (E) Number of nuclear S830 inclusions per ROI, 
the percentage of nuclei with inclusions and average size of nuclear inclusions in pixels (F) Level of expression 
of Pax7 as fold change from WT. Taqman qPCR values were normalized to the geometric mean of Atp5b, Actb 
and Sdha. WT vehicle, n = 8; WT ACVR2B/Fc, n = 7; R6/2 vehicle n = 6; R6/2 ACVR2B/Fc, n = 8. Statistical 
analysis for (B) and (D) was two-way ANOVA with post-hoc Bonferroni correction (see Table S8 for main 
effects) and for (A), (C), (D) and (E) was Student’s t-test (n = 4/treatment group). Statistical significance for 
R6/2 vehicle vs R6/2 ACVR2B/Fc is depicted by *p < 0.05; **p < 0.01; ***p < 0.001 and for WT vehicle vs R6/2 
vehicle by ###p < 0.001. All data presented ± SEM. WT = wild type, ROI = regions of interest.
www.nature.com/scientificreports/
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pathogenic process in HD38. Microarray profiles have been used to identify dysregulated transcripts in specific 
regions of HD post mortem brains39,40 and in quadricep biopsies from HD patients23 as compared to control sub-
jects. Given that the transcriptome is highly dysregulated in the brain12 and skeletal muscle23 of R6/2 transgenic 
mice, we used quantitative real time PCR (qPCR) to investigate the level of expression the ActRIIB receptor 
(Acvr2b) and myostatin (Mstn), and found that the receptor and ligand were expressed at comparable levels in 
WT and R6/2 muscle, hence their transcriptional dysregulation does not contribute to the muscle wasting in R6/2 
mice (Fig. S4). The expression levels of Mstn and Acvr2b were not affected by treatment in either case.
Inhibition of myostatin signaling activates pathways that directly stimulate protein synthesis and inhibit pro-
tein breakdown in the muscle fibre32. In order to uncover the transcriptional changes that underlie the phenotypic 
rescue by ACVR2B/Fc, RNA from the quadriceps and TA of WT and R6/2 mice at 12 weeks of age that had been 
treated with either vehicle or ACVR2B/Fc was sequenced (n = 10/treatment group). Dysregulated gene analy-
sis (DESeq. 2) was applied to identify genes for which there was a statistically significant change in expression 
(Benjamini-Hochberg adjusted p < 0.05). The transcriptional response of WT and R6/2 muscles to ACVR2B/
Fc treatment was relatively comparable (Table S3). We did not see changes in the expression of genes controlled 
by SMAD 2/3-signaling. This is most likely because the RNAseq analysis was performed on tissue harvested one 
week after the last ACVR2B/Fc dose, by which time this response had diminished. The gene ontology (GO) terms 
associated with the few hundred transcripts whose expression levels were altered in response to treatment, in both 
WT and R6/2 mice, were broadly related to muscle function and energy metabolism (Tables S3 and S4).
The comparison of gene expression levels in the quadriceps and TA of R6/2 as compared to WT mice indi-
cated that approximately a half of all genes were dysregulated in these muscles (Table S3). We next analysed the 
effect of ACVR2B/Fc treatment on the extent of transcriptional dysregulation in R6/2 TA and quadriceps. We 
found that the expression level of only a very small number of R6/2-dysregulated genes was changed (cut off of 1.5 
fold change and adjusted to p < 0.05) (detailed in Fig. 6 and Table S4). In some cases, administration of ACVR2B/
Fc restored the expression levels of dysregulated genes toward WT levels, but in others, the extent to which genes 
were dysregulated was increased (Fig. 6, Table S4). Therefore, inhibition of signaling through the ActRIIB recep-
tor had very little impact on the disease-related transcriptional dysregulation in these two muscles. We applied 
weighted gene correlation network analysis (WGCNA), in an attempt to uncover subtle changes in transcriptional 
regulation, which might not have been picked up by DESeq. 2, however, this did not reveal any additional GO 
terms (Tables S5 and S6).
Discussion
Pathophysiological alterations in skeletal muscle contribute to the phenotypes exhibited by mouse models of HD 
(for review see28). Here we have shown that treatment with a soluble ActRIIB receptor (ACVR2B/Fc) completely 
prevented skeletal muscle atrophy and body weight loss from occurring in the R6/2 HD mouse model. Treatment 
prevented the onset of skeletal muscle weakness, contractile abnormalities and the loss of functional motor units 
in EDL muscles. Remarkably, ACVR2B/Fc treatment also delayed the age at which R6/2 mice reached end-stage 
disease.
The deposition of aggregated forms of the HTT protein is the earliest phenotype to have been reported in 
the skeletal muscle of HD mouse models36, and therefore it was important to determine whether treatment with 
ACVR2B/Fc might have modulated this process, which would potentially be indicative of disease modifying 
properties. However, our assessment of the comparative levels of HTT aggregation turned out to be more compli-
cated than anticipated. Our routine approach to measuring HTT aggregation, using the Seprion ELISA, suggested 
that ACVR2B/Fc treatment might have decreased the HTT aggregate load. However, this interpretation was com-
plicated by two factors: the ACVR2B/Fc induced hypertrophy resulted in a lower density of nuclei in the treated 
muscle, potentially diluting the levels of both nuclear and cytoplasmic aggregates; second, the satellite cell pool 
was greater in vehicle than in ACVR2B/Fc treated muscle reflecting attempts by the R6/2 muscle at regeneration 
in response to mutation-induced pathogenic processes. In fact, our immunohistochemical analyses indicated that 
the levels of aggregation in the vehicle and ACVR2B/Fc treated muscles were relatively comparable, although the 
size and frequency of nuclear inclusions differed. The ACVR2B/Fc treated muscle had a lower density of nuclei, 
of which a higher percentage contained larger nuclear inclusions than in the vehicle treated samples. It is possible 
that replenishment of the satellite cell pool in vehicle-treated R6/2 muscle provided a source of ‘younger’ nuclei 
in which the aggregation process was less well advanced. A more detailed analysis of the effect of ACVR2B/Fc on 
HTT aggregation requires a much better baseline understanding of this process in skeletal muscle and is beyond 
the scope of this study at the present time.
Inhibition of myostatin/activin A signaling activated a relatively comparable transcriptional program in both 
WT and R6/2 mice to increase muscle protein synthesis and decrease the degradation of muscle proteins. The 
gene ontology terms associated with these changes were broadly associated with muscle function and energet-
ics. Our RNAseq transcriptome analysis showed that approximately one half of all genes were dysregulated in 
the R6/2 TA and quadriceps at 12 weeks of age as compared to wild type. In light of the complete restoration 
of muscle mass and strength, it was surprising that we found such little evidence of an improvement in this 
HD-associated transcriptional dysregulation. However, this result was compatible with the fact that ACVR2B/Fc 
treatment did not prevent HTT aggregation in nuclei.
The mouse models in which skeletal muscle phenotypes have been described all carry highly expanded 
CAG repeats and represent the severe forms of HD with symptom onset occurring in childhood or adolescence. 
Therefore, is there any evidence that these preclinical findings will be applicable to HD patients with CAG repeat 
expansions that cause the adult onset form of the disease? Although studies are limited, impairments in skeletal 
muscle function have been reported in this patient group. Muscle strength has only been assessed in one study. 
This used a hand-held dynamometer to measure the isometric muscle strength in six lower limb muscle groups 
and found that people with HD had, on average, half the strength of healthy matched controls and that muscle 
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strength significantly correlated with stage of disease as measured by UHDRS (unified Huntington’s disease rat-
ing scale) scores41. Strikingly, myopathy was reported to be the first HD-related symptom in a semi-professional 
marathon runner, which occurred years before the appearance of other neurological symptoms42. Most mech-
anistic studies of the skeletal muscle pathophysiology of HD patients have focused on mitochondrial function 
and energy metabolism. These have revealed a decreased oxidative capacity43,44 and lower anaerobic threshold45 
than in control subjects and deficits in complex II/III activity of mitochondrial respiratory chain46, although nor-
mal mitochondrial function has recently been reported in presymptomatic mutation carriers47. Gene expression 
profiling of the RNA from HD patient skeletal muscle biopsies revealed the beginnings of a transition from fast 
twitch to slow twitch fibres23, consistent with that observed in the mouse models19,23. Histological studies have 
been very limited, often being restricted to the analysis of a single patient, and have reported: multiple centralized 
nuclei44, non-specific myopathic changes48, an abnormal pattern of HTT staining44 and the presence of nuclear 
inclusions46. A systematic longitudinal study of muscle function and pathology at all clinical stages of HD is 
clearly warranted.
Figure 6. The effect of ACVR2B/Fc treatment on genes that are dysregulated in R6/2 muscle. The first column 
in each panel indicates the change in gene expression in R6/2 muscle as compared to WT. Red squares represent 
an increase and blue squares, a decrease in expression levels. The second column represents the change in 
gene expression levels in R6/2 muscle in response to ACVR2B/Fc treatment and the third column indicates 
when a gene in WT muscle was also significantly changed in response to treatment. All of the depicted genes 
were changed to statistically significant levels (adjusted p < 0.05) with a fold change greater than 1.5. Genes in 
bold were changed in both quadriceps and tibialis anterior. The panels represent genes that are (A) increased 
or (B) decreased in the quadriceps and (C) increased or (D) decreased in the tibialis anterior of R6/2 mice as 
compared to WT. RNAseq was performed on RNA extracted from n = 10 mice/treatment group.
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In general, systematic muscle wasting is associated with weakness, fatigue, frailty, insulin resistance, bone frac-
ture, disability and death32. In HD, muscle atrophy and weakness would be expected to exacerbate physical inac-
tivity, which could in turn increase the rate of atrophy41. It may contribute to the frequency of falls and accelerate 
the loss of independent mobility and the use of a wheelchair. It could also lead to an increase in HD-associated 
apathy thereby contributing to cognitive decline. Myostatin inhibition in muscle has been shown to improve 
metabolism, effects that may also be beneficial to individuals with HD49. Therefore, although our data suggest that 
inhibition of myostatin/activin A signalling would provide a symptomatic treatment rather than one targeting 
the underlying pathogenic basis of the disease, this may have considerable impact on the overall quality of life for 
HD patients in terms of increased mobility and a reduction in falls, as well as the cognitive and mood benefits that 
could arise through an increased exercise capacity50,51. Consistent with this approach, myostatin inhibitors are 
currently being tested in clinical trials as a symptomatic treatment for inclusion body myositis34,52 and have been 
proposed as treatments to target the periphery in amyotrophic lateral sclerosis53.
The development of agents that inhibit myostatin signalling has been an active area of research since the 
knock-out of myostatin was shown to induce muscle hypertrophy in mice30. These approaches fall into two main 
categories, those that specifically target myostatin e.g. anti-myostatin antibodies, or those that, like the ACVR2B/
Fc soluble receptor used here, also inhibit signaling via its alternative ligands: activin A, growth differentiation 
factor 11 (GDF11) and bone morphogenic proteins (BMPs)32. Therapeutics that inhibit myostatin/activin A sig-
naling are currently undergoing clinical trials for a wide range of indications which include sarcopenia, cancer 
cachexia, muscular dystrophy, sporadic inclusion body myositis and rehabilitation post-orthopedic surgery (for 
reviews, see34,54). The comparative safety, tolerability and efficacy of these modalities will soon have been estab-
lished34 paving the way to the design of clinical trials to assess the benefits of myostatin inhibition in individuals 
with HD.
Methods
Mouse maintenance, breeding and genotyping. All animal care and procedures were performed in 
compliance with the regulation on the use of Animals in Research (UK Animals and Scientific Procedures Act of 
1996 and the EU Directive of 2010/63/EU) with approval by the King’s College London Ethical Review Process 
Committee. Hemizygous R6/2 mice were bred by backcrossing R6/2 males to (CBA x C57BL/6) F1 females 
(B6CBAF1/OlaHsd, Harlan Olac, Bicester, UK). All animals had unlimited access to water and breeding chow 
(Special Diet Services, Witham, UK), and housing conditions and environmental enrichment were as previously 
described55. Mice were subject to a 12-h light/dark cycle. Genotyping of tail DNA by PCR and measurement of 
the CAG repeat length were performed as previously described36. Dissected tissues were weighed before being 
snap frozen in liquid nitrogen for molecular analyses and stored at −80 °C until further analysis.
ACRB2R/Fc treatment. ACVR2B/Fc was prepared as previously described56 in a series of batches and 
stored at 4 °C in PBS as vehicle. It was administered weekly by subcutaneous injection at 10 mg/kg starting at 5 
weeks of age. For most experiments, the last dose was given at 11 weeks of age and mice were sacrificed one week 
later at 12 weeks. Mice were randomized to treatment groups based on body weight, litter of origin and CAG 
repeat size and investigators were blind to genotype and treatment group throughout each trial. Body weight 
and/or grip strength were measured longitudinally for all experiments to ensure that all batches of ACVR2B/
Fc had comparable efficacious effects (Table S7). A reduction in body temperature can be indicative of an 
adverse response to a treatment. Body temperature was monitored weekly using an infra-red temperature reader 
(ThermoScan Instant Thermometer, Braun) that was reproducibly positioned under the thorax. There was no 
change in body temperature (Fig. S1B), which taken together with other measures of appearance, indicated that 
the treatment was well-tolerated. For the assessment of ACVR2B/Fc treatment on end-stage disease, dosing con-
tinued weekly after 11 weeks of age until it was judged that a mouse had reached its humane end-point (Table S2). 
A summary of the mice used in each experiment and their CAG repeat size is listed in Table S7.
Assessment of motor-related tasks. Grip strength was measured as previously described57. For the 
initial pilot study, fore-limb grip strength was measured using a San Diego Instruments Grip Strength Meter 
(San Diego, CA, USA) and for subsequent experiments, fore-limb grip strength and also the combined fore- and 
hind-limb grip strength were measured using a grip strength meter from Bioseb in Vivo Research Instruments. 
Mice were tested for motor co-ordination as previously described58 on an Ugo Basile accelerating rotarod (Linton 
Instruments, UK) that had been modified with a smooth rubber coating over the beam55. General ambulation 
was probed in square, plain white arenas (50 × 50 × 50 cm, Engineering Design Plastics Ltd, Cambridge, UK) for 
30 min and behaviour was recorded through a video camera positioned above the apparatus. Activity (distance 
moved) was tracked and then analysed using Ethovision 7XT software (Noldus, Netherlands) as described57.
Assessment of muscle function in vivo. Twelve week old female WT and R6/2 mice that had been treated 
with vehicle or ACVR2B/Fc were deeply anesthetized with isoflurane. The distal tendons of the tibialis anterior 
(TA) and extensor digitorum longus (EDL) muscles in both hindlimbs were dissected free and the isometric ten-
sion was recorded in vivo as described in detail elsewhere35. The contractile characteristics were determined by 
measuring the time taken (ms) for the muscle to elicit peak twitch tension (time to peak, TTP) and the time taken 
for the muscle to reach half relaxation from peak contraction (half relaxation time). Tetanic contractions were 
measured as previously described35 and recorded on a Lectromed Multitrace 2 recorder (Lectromed Ltd, UK). 
All parameters were measured using the Picoscope v5 and v6 software (Pico Technology, Cambridgeshire, UK). 
The number of functional motor units innervating the EDL muscles was determined as described previously35.
Immunohistochemistry and lesser fibre diameter measurements. Muscles were dissected, embed-
ded, frozen in isopentane and sectioned as previously described59. Immunohistochemical staining was performed 
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using the Ventana Discovery XT instrument, using the Ventana DAB Map Kit (760–124). Anti-laminin (Sigma 
L9393) primary antibody incubation was for 1 h using a 1:1000 dilution. Swine anti- Rabbit (Dako E0353) sec-
ondary antibody incubation was for 32 min, using a 1:200 dilution. Slides were haematoxylin counterstained.
Analysis of laminin stained muscle sections was performed on whole slide images, generated using a Leica 
SCN400F, using Definiens Developer XD (Definiens, Munich, Germany) and between 3 and 8 tissue sections were 
analysed per mouse. An automatic threshold method was used to separate the tissue from the background area, 
then again to identify sarcolemma within the tissue. A series of shape based manipulations and edge smoothing 
operations were then performed to separate joined fibres, combine split fibres and clarify the definition of muscle 
fibres. Finally muscle fibres which do not satisfy strict morphometric rules were excluded to provide a reliable set 
of transversely sectioned muscle fibres; width and shape measurements were then exported. The fibre diameter 
profile each tissue section was generated in excel.
MR Imaging and sample preparation. The methods for sample preparation, scanning and data process-
ing are described in detail in the Supplemental Information.
HTT aggregation analysis by ELISA and immunohistochemistry. Aggregates were captured in 
Seprion ligand coated plates (Microsens, PADPCB1 SEP1–01) and detected using the MW8 mouse monoclonal 
antibody60 (1:2000) as previously documented36. For immunohistochemistry, muscles were dissected, embedded, 
frozen in isopentane and sectioned as described59 and slides were stored −20 °C until processing for immuno-
histochemistry. Prior to staining, slides were equilibrated to 50 °C to remove moisture and a wax pen was used 
to create a hydrophobic barrier around the sections. After washing with PBS, sections were blocked using 10% 
normal donkey serum and 0.3% triton X-100 in PBS. Antibodies against laminin (Sigma L9393, 1:1000) and 
HTT (S83061, 1:1000) were applied overnight at 4 °C prior to the application of appropriate secondary antibodies 
(Molecular Probes, 1:500) at RT for 2 h followed by the DAPI nuclear stain for 15 min.
Confocal focal images were taken using the Nikon AR1 Confocal microscope (Nikon Instruments using a 40x 
objective (Plan Apo 40x Ph2, NA 0.95) and NIS-Elements C software (Nikon Instruments). A grid was applied 
to capture nine regions of interest (ROI) per section through an automated unbiased process from two muscle 
sections per mouse (n = 4 mice per treatment group) to generate 18 captured ROIs per mouse. Images were 
exported as TIFFs and analysed using threshold fluorescence levels in ImageJ (U. S. National Institutes of Health, 
http://imagej.nih.gov/ij/) (Fig. S2A and C). A threshold intensity value of 90 was applied to DAPI images and of 
50 to S830 images, and pixels below these thresholds were excluded. The S830 signal in the sections from WT 
mice treated with either vehicle or with ACVR2B/Fc was negligible (Fig. S3C). Objects were identified as groups 
of adjacent pixels. Objects with less than 25 DAPI pixels were considered debris and not counted as nuclei. DAPI 
threshold images were used to mask the S830 images and co-localised pixels were counted as intra-nuclear inclu-
sions and those not co-localising were considered to be extra-nuclear inclusions (Fig. S3B). The percentage of 
nuclei containing inclusions was counted manually.
RNA extraction and Taqman real-time PCR expression analysis. Total RNA from skeletal muscles 
was extracted with the mini-RNA kit according to the manufacturer instructions (Qiagen). The reverse tran-
scription reaction (RT) was performed using MMLV superscript reverse transcriptase (Invitrogen) and random 
hexamers (Operon) as described elsewhere19,62. The final RT reaction was diluted 10-fold in nuclease free water 
(Sigma). All Taqman qPCR reactions were performed as described previously62 using the CFX96 Real-Time PCR 
Detector (BioRad). Stable housekeeping genes for qPCR profiling of various skeletal muscles for HD mouse mod-
els were determined using the Primer Design geNorm Housekeeping Gene Selection Mouse Kit with PerfectProbe 
software. Estimation of mRNA copy number was determined in triplicate for each RNA sample by comparison to 
the geometric mean of three endogenous housekeeping genes (Primer Design) as described62. Primer and probe 
sets for genes of interest were purchased from Thermo Fisher Scientific.
RNA sequencing and data analysis. RNA was prepared from the quadriceps and tibialis from n = 10 
mice per treatment group and sequencing was performed by Expression Analysis on an Illumina Hi-seq. 2000. 
Paired-end sequencing was obtained, 4-plexed across lanes for a minimum of 38 million 50mer paired reads per 
sample. Alignment and QC was conducted in Omicsoft using the OSA algorithm63 against the mouse genome 
version B38 with EMSEMBL gene models version R75. FPKMs were then calculated following standard formulas. 
QC assessment found 79 of 80 samples of high quality both at the RNA quality and alignment mapping levels. 
One sample (quadriceps mouse 93) was found to be a strong outlier by principal component analysis and omit-
ted from the analysis. The RNAseq data have been deposited in the GEO database under the accession number 
GSE81367. Rounded counts to the next integer were used as input data for dysregulated gene analysis (DESeq. 
2)64. Only genes with a count of 2 or more in at least 10 out of the 79 samples were used for the analysis which 
left 18558 genes in the dataset. For weighted gene co-expression network analysis (WGCNA) we used variance 
stabilizing transformed counts from the DESeq. 2 output (function varianceStabilizingTransformation) as input. 
The subsequent WGCNA analysis was carried out as previously described40. Soft-threshold power for all networks 
was 30. Modules with highly correlated module eigengenes were merged (r > 0.7). Enrichment analysis was car-
ried out using Enrichr http://amp.pharm.mssm.edu/Enrichr/index.html 65. We used the gene lists of dysregulated 
genes or the identified network modules as input. We summarized all gene ontology terms (GO-term) of similar 
sub-terms into an overarching term. Only GO-terms, regulators, pathways, etc. with a combined score larger than 
5 were considered.
Statistics. Data were graphed using Prism Ver.5.0b (Graphpad software, California USA). Statistical analy-
ses were calculated using SPSS Statistics Ver. 22 (IBM Portsmouth, UK). Data were screened for statistical out-
liers using Grubb’s test (GraphPad software, California, USA). The total number of mice used in each of the 
www.nature.com/scientificreports/
1 2SCIeNtIfIC RepORtS | 7: 14275  | DOI:10.1038/s41598-017-14290-3
experiments is summarised in Table S7. The datasets can be separated into those that were collected longitudi-
nally and those that were collected at a single time point.
Longitudinal datasets. These include assessment of body weight, body temperature, grip strength, locomo-
tor activity and rotarod performance. To probe the influence of treatment across time, a two-way ANOVA was 
employed (Treatment group and Age as between-subject factors). All main effects from ANOVAs can be found 
in Table S8. Post-hoc tests with a Bonferroni correction for multiple comparisons were applied where appropriate 
and represented in the figures and in Table S9.
Datasets takes at a single time point. These include muscle mass, fibre diameters, muscle physiological measures, 
assessment of aggregate load by Seprion ELISA and qPCR. To probe the influence of genotype and treatment on 
these measures, either a two-way ANOVA was applied (Genotype and Treatment as between-subject factors) or 
a one way ANOVA to compare Treatment Groups. All main effects from ANOVAs can be found in Table S8 or 
in the text. Post-hoc tests with a Bonferroni correction for multiple comparisons were applied where appropriate 
and represented in the figures and in Table S9.
End-stage disease was determined using a scoring system that combined an assessment of appearance, body 
weight, disease score and unprovoked behaviour (Table S2). The data were represented by a Kaplan-Meier cumu-
lative survival curve and statistical analysis was performed in SPSS using the log-rank (Mantel-Cox) test.
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